QIAGEN Aktie
WKN: 901626 / ISIN: NL0012169213
|
06.08.2025 00:31:20
|
QIAGEN Reports Strong Q2 Results, Raises Full-Year Sales Outlook
(RTTNews) - QIAGEN N.V. (QGEN) reported financial results for the second quarter of 2025 and also lifted its full-year net sales growth outlook. Net sales for the quarter rose 7 percent year-over-year to $534 million, or 6 percent at constant exchange rates. Net income reached $96 million, compared to a loss of $183 million in the same period last year. Earnings per share stood at $0.44, reversing a loss of $0.82 per share in the second quarter of 2024. On an adjusted basis, net income increased 8 percent to $132 million, while adjusted diluted EPS climbed 9 percent to $0.60. QIAGEN revised its full-year 2025 outlook, and now expects net sales to grow 4 to 5 percent at constant exchange rates, up from its prior forecast of around 4 percent. The company projects core business sales to grow 5 to 6 percent CER, excluding discontinued products.
QGEN closed Tuesday's trading at $49.95, down $0.30 or 0.60 percent on the New York Stock Exchange.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu QIAGEN N.V.mehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu QIAGEN N.V.mehr Analysen
| 07.02.24 | QIAGEN Hold | Jefferies & Company Inc. |